---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-015693"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T20:43:13.667715+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology Q1 2023: Cash $97M, first patient dosed in ONSEMBLE trial

## Summary
- Cash, cash equivalents & short-term investments of $97M as of March 31, 2023; projected runway into 2025.
- First patient dosed in Phase 2 ONSEMBLE trial of onvansertib for KRAS/NRAS-mutated metastatic CRC.
- Appointed Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer.
- Operating expenses $12.1M in Q1 2023, up from $11.1M in Q1 2022.
- Net cash used in operations $8.7M in Q1 2023, compared to $10.2M in Q1 2022.

## SEC filing metadata
- accession: 0001628280-23-015693
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000162828023015693/0001628280-23-015693-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000162828023015693/crdf-20230504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-015693
- JSON: https://secwatch.observer/filing/0001628280-23-015693.json
- Plain text: https://secwatch.observer/filing/0001628280-23-015693.txt

## Key facts
- Earnings Releases
  Cardiff Oncology, Inc. reported financial results for first quarter ended March 31, 2023.
  - Period: first quarter ended March 31, 2023
  - Result: reported results
  source text: On May 4, 2023, Cardiff Oncology, Inc. issued a press release announcing company highlights and financial results for the first quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1213037/000162828023015693/0001628280-23-015693-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.